The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients
Abstract
Clinical outcomes of gastrointestinal stromal tumor (GIST)-bearing patients treated with imatinib mesylate (IM) are variable. Other than the site of mutation within the c-kit gene, prognostic features of GIST remain undefined. IM can exhibit off-target effects such as triggering natural killer (NK) cell activity. We addressed whether NK cell functions could predict long term survival with IM. NK cell functions were followed up in 77 GIST patients enrolled onto two phase III trials. "Immunologic responders" were defined as patients whose NK cell IFN-gamma values after 2 months of IM were higher than or equal to the baseline value at entry into the trial. The prognostic effect of IFN-gamma on progression-free survival was assessed by a Wald test in a Cox regression analysis using the landmark method and stratified by trial and on the c-kit mutational status. Fifty-six patients were evaluable for the NK cell IFN-gamma responses at baseline and 2 months. Their median follow-up for progression-free survival was 3.7 years. Thirty-four of 56 patients were immunologic responders to IM. In the Cox regression analysis, immunologic responders possessed a hazard ratio of progression or death equal to 0.29 (95% confidence interval, 0.12-0.70; P = 0.006) compared with nonresponders. Kaplan-Meier 2-year survival estimates were 85% for immunologic responders and 50% for nonresponders. Moreover, the immunologic response added prognostic value to the c-kit mutation. The NK cell IFN-gamma production after 2 months of treatment could be considered an independent predictor of long term survival in advanced GISTs treated with IM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the clinical activity of imatinib in individuals with GIST is linked to IFNG production by the patient's NK cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Menard et al., 2009
In the citing paper
“Imatinib was arguably the first targeted anticancer agent to demonstrate immunostimulatory effects that are directly linked to NK-cell activation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Menard et al., 2009
Citations
Cites
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490 · cited 1×
“Indeed, the sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (2) from GIST-bearing patients, revealed mutations in the region between the transmembrane and tyrosine kinase domains (2).”
BackgroundEffectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“The renaissance of NK cells in tumor immunosurveillance can be attributed to the discovery of stress-induced ligands for NK cell–activating receptors (20) and the relevance of MHC class I/Killer Inhibitory Receptor interactions in mismatched hematopoietic transplants causing NK cell–mediated graft versus leukemia effe…”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 2×
“Other drugs may have side effects that stimulate the immune system, by transient lymphodepletion (7), by the subversion of immunosuppressive mechanisms (33, 35), or by direct or indirect stimulatory effects on immune effectors (36, 37).”
BackgroundSelf-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“Although cancer chemotherapy and radiotherapy is often viewed as a strategy that mainly affects tumor cells, accumulating evidence indicates that, depending on the lethal stimulus, tumor cell death can elicit a specific immune response that contributes to the therapeutic effect (29, 33, 34).”
BackgroundSelf-citationActivation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999 · cited 1×
“The renaissance of NK cells in tumor immunosurveillance can be attributed to the discovery of stress-induced ligands for NK cell–activating receptors (20) and the relevance of MHC class I/Killer Inhibitory Receptor interactions in mismatched hematopoietic transplants causing NK cell–mediated graft versus leukemia effe…”
BackgroundCancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823 · cited 2×
“Other drugs may have side effects that stimulate the immune system, by transient lymphodepletion (7), by the subversion of immunosuppressive mechanisms (33, 35), or by direct or indirect stimulatory effects on immune effectors (36, 37).”
BackgroundKinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299 · cited 2×
“From these 56 patients, 38 patients have been evaluated for c-kit mutation status (14) at exon 11, which predicted the response to IM (3).”
BackgroundResultTaking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,127 · cited 1×
“Lymph nodes contain several subsets of DCs that are critical links between innate and cognate immune responses (22).”
BackgroundImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Self-citationVerweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665 · cited 2×
“trial 62005 (8) and 43 GIST patients included in the French Sarcoma Group”
Self-citation
Cited by
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
“Biomarker discovery programs revealed that imatinib can activate peripheral NK cells from patients with GIST to produce IFNg, and that the magnitude of such response predicts the efficacy of treatment (Ménard et al., 2009).”
BackgroundSelf-citationHiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Self-citationZitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
“…of specific isoforms of the NK cell-activating receptor NKp30 (Delahaye et al., 2011), the imatinib-induced production of interferon-g (IFN-g) by circulating NK cells (Borg et al., 2004; Ménard et al., 2009), as well as the frequency of tumor-infiltrating NK cells (Rusakiewicz et al., 2013).”
BackgroundSelf-citation
Metadata
- Authors
- Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., Flament, C., Emile, J.-F., Le Cesne, A., & Zitvogel, L.
- Affiliations
- 1Institut National de la Santé Et de la Recherche Médicale (INSERM), Unit U805 "Tumor immunology and immunotherapy,"
- Centre Léon Bérard (FR)
- Inserm (FR)
- 3Statistics,
- 4Medicine, Dermatology Unit, and
- 7Department of Pathology and INSERM U602, Hôpital Ambroise Paré, Boulogne, France; and
- 5Medicine, Institut Gustave Roussy, Villejuif, France;
- Université Paris-Sud (FR)
- ORCID
- Venue
- Cancer Research
- Published
- 2009-04-15
- Volume
- 69
- Issue
- 8
- Pages
- 3563-3569
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1964703707
- Cited by
- 202
- References
- 47
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 9 · 2023: 7 · 2022: 10 · 2021: 7 · 2020: 17 · 2019: 7 · 2018: 7 · 2017: 15 · 2016: 14 · 2015: 17 · 2014: 20 · 2013: 24 · 2012: 17
- FWCI
- 12.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gastrointestinal stromal tumor, imatinib mesylate, natural killer cells, interferon-gamma, immune response, prognostic factors, progression-free survival, KIT mutations, long-term survival
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Dendritic Cells, Exons, Female, Humans, Interferon-gamma, Interleukin-2, Killer Cells, Natural, Male, Middle Aged, Piperazines, Pyrimidines, Proto-Oncogene Proteins c-kit, Gastrointestinal Stromal Tumors, Natural Cytotoxicity Triggering Receptor 3, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-3807
- The paper
- Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., Flament, C., Emile, J.-F., Le Cesne, A., & Zitvogel, L. (2009). Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-3807
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.